TRIM32, which is also implicated in breast cancer, is overexpressed in NSCLC, inducing cell proliferation, colony formation, and invasion, and mediating cisplatin chemotherapy resistance through activation of the NF-κB/Bcl-2 signaling pathway. Here, BCL2 is linked to non-small cell lung carcinoma.